Ocular Therapeutix (NASDAQ:OCUL) Insider Namrata Saroj Sells 35,370 Shares of Company Stock

Ocular Therapeutix, Inc. (NASDAQ:OCUL) insider Namrata Saroj sold 35,370 shares of the firm’s stock in a transaction on Thursday, November 5th. The stock was sold at an average price of $6.55, for a total value of $231,673.50. Following the transaction, the insider owned 220,522 shares in the company, valued at $1,444,419.10. The trade was a 13.82% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Ocular Therapeutix Stock Up 3.9%

NASDAQ OCUL traded up $0.26 on Monday, reaching $6.85. 3,554,946 shares of the stock traded hands, compared to its average volume of 3,877,324. The company has a debt-to-equity ratio of 0.14, a quick ratio of 13.03 and a current ratio of 13.10. The company has a fifty day moving average price of $8.40 and a 200-day moving average price of $9.02. The company has a market cap of $1.50 billion, a price-to-earnings ratio of -4.82 and a beta of 1.22. Ocular Therapeutix, Inc. has a 12 month low of $6.00 and a 12 month high of $16.44.

Ocular Therapeutix (NASDAQ:OCUL) last posted its quarterly earnings results on Monday, November 9th. The biopharmaceutical company reported ($0.42) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.06). The firm had revenue of $12.87 million for the quarter, compared to the consensus estimate of $14.27 million. Ocular Therapeutix had a negative return on equity of 59.89% and a negative net margin of 579.10%. Ocular Therapeutix’s quarterly revenue was down 11.5% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.38) EPS. As a group, research analysts forecast that Ocular Therapeutix, Inc. will post -1.47 EPS for the current fiscal year.

Key Ocular Therapeutix News

Here are the key news stories impacting Ocular Therapeutix this week:

• Neutral Sentiment: Investors are also watching for updates on the timing of a potential AXPAXLI filing; the earnings-preview coverage identified this as a key point of focus, but the provided reports do not specify a timing change. Ocular Therapeutix Earnings Preview: AXPAXLI Filing Timing in Focus
• Negative Sentiment: OCUL reported a quarterly loss of $0.42 per share, worse than analysts’ $0.36 expected loss and the $0.37 loss a year earlier. Revenue of $12.87 million also fell short of the $14.27 million consensus and declined 11.5% year over year. The earnings miss and weaker sales were cited as reasons for the share-price pressure. Ocular Therapeutix falls on third quarter earnings miss
• Negative Sentiment: Coverage also pointed to pipeline-related AXPAXLI costs alongside declining DEXTENZA sales, highlighting pressure from development spending and the commercial performance of an existing product. Ocular Therapeutix Q3 2026: AXPAXLI Pipeline Costs Bite as DEXTENZA Slides

Wall Street Analysts Forecast Growth

A number of research analysts have commented on the stock. HC Wainwright reissued a “buy” rating on shares of Ocular Therapeutix in a research report on Tuesday, October 20th. Needham & Company LLC reaffirmed a “buy” rating and issued a $18.00 price target on shares of Ocular Therapeutix in a research report on Monday, October 19th. Wall Street Zen upgraded shares of Ocular Therapeutix from a “sell” rating to a “hold” rating in a research note on Saturday, August 8th. UBS Group started coverage on shares of Ocular Therapeutix in a report on Sunday, October 11th. They set a “buy” rating and a $14.00 price objective on the stock. Finally, Chardan Capital reissued a “buy” rating and issued a $23.00 price objective on shares of Ocular Therapeutix in a research note on Friday, October 2nd. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Ocular Therapeutix currently has a consensus rating of “Moderate Buy” and an average target price of $23.33.

Hedge Funds Weigh In On Ocular Therapeutix

Several institutional investors and hedge funds have recently added to or reduced their stakes in OCUL. Rockefeller Capital Management L.P. purchased a new stake in shares of Ocular Therapeutix during the fourth quarter valued at about $31,000. Integrated Wealth Concepts LLC bought a new stake in shares of Ocular Therapeutix in the 2nd quarter valued at about $51,000. Sterling Capital Management LLC boosted its holdings in shares of Ocular Therapeutix by 401.7% in the 3rd quarter. Sterling Capital Management LLC now owns 6,612 shares of the biopharmaceutical company’s stock valued at $51,000 after buying an additional 5,294 shares in the last quarter. Root Financial Partners LLC purchased a new position in shares of Ocular Therapeutix in the 3rd quarter worth approximately $66,000. Finally, Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of Ocular Therapeutix in the 3rd quarter worth approximately $86,000. Hedge funds and other institutional investors own 59.21% of the company’s stock.

About Ocular Therapeutix

Ocular Therapeutix, Inc is a biopharmaceutical company focused on developing and commercializing treatments for eye diseases and conditions. Based in Bedford, Massachusetts, the company uses its proprietary hydrogel-based technology to deliver medicines to the eye over time.

Its marketed product, DEXTENZA, is a corticosteroid insert placed in the tear duct by an eye-care professional to treat inflammation and pain following ophthalmic surgery. Ocular Therapeutix also develops investigational therapies for retinal diseases and other eye conditions, including treatments designed for sustained drug delivery.

The company was founded in 2006 and serves the U.S.